Last reviewed · How we verify

Far East Bio-Tec Co., Ltd — Portfolio Competitive Intelligence Brief

Far East Bio-Tec Co., Ltd pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Baqiyatallah Medical Sciences University · 1 shared drug class
  2. Bristol-Myers Squibb · 1 shared drug class
  3. Community Research Initiative of New England · 1 shared drug class
  4. Drugs for Neglected Diseases · 1 shared drug class
  5. DualityBio Inc. · 1 shared drug class
  6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 shared drug class
  7. French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
  8. Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Far East Bio-Tec Co., Ltd:

Cite this brief

Drug Landscape (2026). Far East Bio-Tec Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/far-east-bio-tec-co-ltd. Accessed 2026-05-16.

Related